shutterstock-141389161-web
racorn / Shutterstock.com
15 January 2015Americas

Jazz plays on as Xyrem challenges quashed

The US Patent and Trademark Office (USPTO) has rejected several petitions that challenged a patent covering Jazz Pharmaceuticals’ narcolepsy drug Xyrem (sodium oxybate).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
17 July 2018   The US Court of Appeals for the Federal Circuit has rejected Jazz Pharmaceuticals’ attempt to revive patents covering its narcolepsy drug Xyrem.